Gradalis
Biotechnology, 2545 Golden Bear Dr Ste 110, Carrollton, Texas, 75006, United States, 11-50 Employees
Phone Number: 21********
Who is GRADALIS
Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovaria...
Read More
-
Headquarters: 2545 Golden Bear Dr Ste 110, Carrollton, Texas, 75006, United States
-
Date Founded: 2003
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2451
|
NAICS Code: 561110 |
Show More
Gradalis Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Gradalis
Answer: Gradalis's headquarters are located at 2545 Golden Bear Dr Ste 110, Carrollton, Texas, 75006, United States
Answer: Gradalis's phone number is 21********
Answer: Gradalis's official website is https://gradalisinc.com
Answer: Gradalis's revenue is $10 Million to $25 Million
Answer: Gradalis's SIC: 2451
Answer: Gradalis's NAICS: 561110
Answer: Gradalis has 11-50 employees
Answer: Gradalis is in Biotechnology
Answer: Gradalis contact info: Phone number: 21******** Website: https://gradalisinc.com
Answer: Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The companys proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types. About Vigil Vigil is the first cellular therapy to show positive survival benefits in a randomized controlled clinical study of patients with solid tumors. Vigil is a self-navigating cellular immunotherapy that addresses the major deficits of leading cancer treatments. Vigil uses all of a patients tumor-related antigens to identify cancer cells and then enhances the training of the immune system to recognize and attack those cells. Gradaliss proprietary bi-shRNA platform accomplishes this via three key functions: (1) it blocks furin, the enzyme that generates the immunosuppressive cytokines TGF beta types 1 and 2; (2) it activates effector cells including antigen-presenting dendritic cells and CD8+ T cells via the production of GM-CSF; and (3) it induces an immune response to the full complement of neo-antigens from the patients tumor via intradermal administration. In a Phase 2b trial, Vigil showed a positive trend in the primary endpoint of recurrence-free survival in the overall population and a significant improvement in recurrence-free survival and overall survival in a pre-planned subgroup analysis of Stage III/IV newly diagnosed ovarian cancer patients with the BRCA wild type (BRCA-wt) molecular profile. The company is preparing to initiate a clinical study intended for product registration in patients in this subgroup. Additionally, Phase 1 results in an all-comer trial have shown positive signals of activity in multiple tumor types.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month